Conference Day Two

Hari Persidangan 2

科学议程第一天

8:00 am Coffee & Networking

8:45 am Chair’s Opening Remarks

  • Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

Revolutionizing Solid Tumor Treatments in 2024: Combining Approaches for Effective Targeting and Optimised CAR-T Strategies for Increased Patient Benefits

9:00 am Session Details to Be Confirmed

  • Christy Ma Chief Executive Officer, SCG Cell Therapy

9:30 am Harnessing Immune Cell Therapies for Better Clinical Efficacy Against Solid Tumors

10:30 am Morning Refreshments & Networking

Optimising Robust Manufacturing & CMC Strategies to Fast Track Scaling Up & Scaling Out

11:00 am Innovative Microfluidic Processing for Autologous Cell Therapy

  • Lim An Eng Scientist, Bioprocessing Technology Institute (BTI), A*STAR

11:30 am Differentiating National GMP Infrastructure from Industry GMP Setups

  • Francesca Lim Chief Medical Officer, Senior Consultant, Deputy Head & Assistant Medical Director, Singapore General Hospital, Singhealth, HSA & ACTRIS

12:00 pm Manufacturing Case Study: Preparing from Lab to Trial to Scaling Out

12:30 pm Commercial Therapy Case Study: Optimising Manufacturing Strategies of CAR-T Cells to Align Capacity to Patient Demand

  • Chien-Tsun Kuan President, Chief Executive Officer & Co-Founder, ARCE Therapeutics

1:00 pm Lunch & Networking

Highlighting Key Considerations for Developing Robust Infrastructures for Cell Therapy Commercialisation and Investment

2:00 pm Expanding Horizons: IASO Bio’s Strategic Entry into Southeast Asia

  • Alan Fu Chief Financial Officer, Nanjing Iaso Biotherapeutic

2:30 pm Controlling Cost of Goods During Throughout Manufacturing & Scale-Up Operations

  • Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

3:00 pm Afternoon Refreshments & Networking

4:00 pm Gaining Strategic Investments for Cell Therapy Innovations from Venture Lenders & Investors: From Bedside to Bankside, From Wallstreet to Mainstreet

  • Yang Liu Vice President & Venture Partner, China Credit Enhancement Corporation

4:30 pm Developing Robust Strategies for Successful Cell Therapy Commercialisation & Market Access

  • Rebu Ninan Head of Commercial & Market Access, Immuneel Therapeutics

5:00 pm Chair’s Closing Remarks

  • Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

5:15 pm Close of Summit